Skip to content
Homepage
Author:
NORTHWEST BIOTHERAPEUTICS, INC.
Posted Date:
July 8, 2026
Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses
NORTHWEST BIOTHERAPEUTICS, INC.
July 8, 2026
Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting
NORTHWEST BIOTHERAPEUTICS, INC.
July 2, 2026
